Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production.
about
The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory DiseasesDisease-promoting effects of type I interferons in viral, bacterial, and coinfectionsPlatelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway.Extracts of the rat tapeworm, Hymenolepis diminuta, suppress macrophage activation in vitro and alleviate chemically induced colitis in miceProresolving lipid mediators and mechanisms in the resolution of acute inflammationTumor-secreted PGE2 inhibits CCL5 production in activated macrophages through cAMP/PKA signaling pathway.Cyclic AMP Signaling through Epac Axis Modulates Human Hemogenic Endothelium and Enhances Hematopoietic Cell Generation.Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages.Different phosphoinositide 3-kinase isoforms mediate carrageenan nociception and inflammationActivation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1PGE2 induced in and released by dying cells functions as an inhibitory DAMPCyclic AMP: master regulator of innate immune cell function.Expression of genes associated with immunity in the endometrium of cattle with disparate postpartum uterine disease and fertility.Bacterial lipopolysaccharide induces an endocrine switch from prostaglandin F2alpha to prostaglandin E2 in bovine endometriumCyclic AMP increases COX-2 expression via mitogen-activated kinase in human myometrial cells.EPAC proteins transduce diverse cellular actions of cAMP.Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses.A classical PKA inhibitor increases the oncolytic effect of M1 virus via activation of exchange protein directly activated by cAMP 1.The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function.Prostaglandin E2 As a Modulator of Viral Infections.Phosphodiesterase 4B negatively regulates endotoxin-activated interleukin-1 receptor antagonist responses in macrophages.Apremilast as a treatment for psoriasis.Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway.Prostaglandin E(2) couples through EP(4) prostanoid receptors to induce IL-8 production in human colonic epithelial cell lines.Expression of prostaglandin E receptor subtype EP4 in conjunctival epithelium of patients with ocular surface disorders: case-control study.Vesicular Trans-Cell Wall Transport in Fungi: A Mechanism for the Delivery of Virulence-Associated Macromolecules?Tick saliva suppresses IFN signalling in dendritic cells upon Borrelia afzelii infection.Aspirin in the aetiology of Crohn's disease and ulcerative colitis: a European prospective cohort study.IFN-β: A Contentious Player in Host-Pathogen Interaction in Tuberculosis.Prostaglandin E2 Inhibition of IL-27 Production in Murine Dendritic Cells: A Novel Mechanism That Involves IRF1.Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.Phosphodiesterase inhibitors suppress Lactobacillus casei cell-wall-induced NF-κB and MAPK activations and cell proliferation through protein kinase A--or exchange protein activated by cAMP-dependent signal pathway.
P2860
Q26750377-98B1FA47-675E-429B-B0BF-218F690C1E25Q28082841-700A9024-BB78-4F1C-8FE8-533408FBFCB2Q33411077-3ED0CEC8-9721-4BD3-BEF4-523662F935E2Q33675810-7F1497FD-7D72-4C7D-979B-ACC6E1866362Q34411426-C7432635-BC30-4C05-8C61-897AA233F27DQ34503208-2A182E8F-020B-4EB3-9E0B-55FD5C5933FBQ36000144-3717D27E-E8AC-4AF2-B066-23E45EF2803DQ36342694-D99B1FE3-A1BA-4AD2-88A8-0371EFD3A98DQ36458539-675D8DB1-1AB6-4B5B-B466-0673DF5FF44CQ36582828-3445B32E-69DA-49A5-99E9-C867BEF62578Q36802436-AB4E634B-B053-4C8E-88D9-F1C1DE52C5F1Q37103511-63BE62E4-7494-4A96-A740-4C22E25EA2DAQ37242445-2F3B67E5-ECD5-4361-9E70-0488F914E8A9Q37252064-0B2303B6-9923-49AC-A97F-C61B09C2AFD6Q37295519-32E83E8F-D93E-47D5-8A97-C560BFAA2DD1Q37390882-ECA676B2-2E12-44A0-A29A-9CE276ABEC00Q37559660-448E9C3B-9D3F-4853-BDAB-5936BAE6F2B1Q37565501-CB8C3766-7BCD-4D77-A31C-9EFDC9641CF0Q37632467-B7DCFEC0-3490-4E73-A48E-582DD94B5F3EQ37639791-877F0322-436B-410B-B31D-E703A6FD399EQ37739683-1F86B9C3-A2B4-4F35-BD4A-7A77FEFA5152Q38019980-1604DE47-7246-40E6-87C7-0241946DEE5AQ41416602-CFB02598-74C4-4C92-84FA-CCA347B1F216Q41429559-93EE8B9B-080A-489E-9FCB-7C9127399D0BQ41505221-BF05E527-F6F8-453F-98AE-DBE5DF56E550Q41816656-6D9E2770-2D08-4159-AD72-AD64D640189AQ44329057-9FE3560F-FC1B-40BA-98AA-E7A578447C98Q45448545-42D42315-0372-4332-AE0C-048F7B3D3B74Q47274901-38C8D68C-BE8F-4D7D-82FC-62358A869449Q48375812-3349CB20-415F-459A-B239-931A78AC8944Q52656382-6D0C13E1-4793-47F8-A30D-2E1B0F21600CQ54508086-E8B0811B-224D-4C01-A5B3-271DF48631DC
P2860
Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production.
@ast
Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production.
@en
type
label
Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production.
@ast
Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production.
@en
prefLabel
Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production.
@ast
Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production.
@en
P2093
P2860
P1476
Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production.
@en
P2093
Balduino Mastrofrancesco
Jonathan S Reichner
William L Henry
X Julia Xu
P2860
P304
P356
10.4049/JIMMUNOL.180.4.2125
P407
P577
2008-02-01T00:00:00Z